Pacira BioSciences Reports Third Quarter 2020 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Pacira Pharma (PCRX) Tops Q3 EPS by 7c, Revenues Beat
October 29, 2020 8:07 AM EDTPacira Pharma (NASDAQ: PCRX) reported Q3 EPS of $0.68, $0.07 better than the analyst estimate of $0.61. Revenue for the quarter came in at $117.5 million versus the consensus estimate of $115.15 million.
Third Quarter 2020 Financial Results
Total revenues were $117.5 million in the third quarter of 2020, a 12% increase versus the $104.7 million reported for the third quarter of 2019.EXPAREL net product sales were $113.7 million in the third quarter of 2020, a 12% increase versus the $101.5 million reported for the third quarter of 2019.Third quarter 2020 iovera° net product sales were $2.7 million, a 3% increase versus the $2.6 million reported for the... More